Repotrectinib clinical trials
Also written TPX-0005 and BMS-986472.
How each study uses repotrectinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the repotrectinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 15 Nov 2023 · AUGTYRO · NDA 218213 (FDA, Drugs@FDA)
- European Union
- 13 Jan 2025 · Augtyro · EMEA/H/C/006005 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2024 (5)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 5 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 5
Turning Point Therapeutics, Inc. (5) · Bristol-Myers Squibb (4) · MedSIR (1) · Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer (1) · Memorial Sloan Kettering Cancer Center (1) · Instituto Oncológico Dr Rosell (1) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test repotrectinib, phase 3 first.
- Feb 2027A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)Phase 3 · Bristol-Myers Squibb
- Mar 2027Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain MetastasisPhase 2 · MedSIR
Studies
Open first, then newest update. How each study uses repotrectinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsRecruitingPhase 1/2Turning Point Therapeutics, Inc.NCT04094610Written as Oral repotrectinib (TPX-0005)
- Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain MetastasisRecruitingPhase 2MedSIRNCT06315010Written as Repotrectinib
- Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLCRecruitingPhase 2Centre Hospitalier Intercommunal de Toulon La Seyne sur MerNCT06552234Written as Repotrectinib
- A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor CancerRecruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT05004116Written as Repotrectinib
- A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsRecruitingPhase 1/2Turning Point Therapeutics, Inc.NCT03093116Written as Oral repotrectinib (TPX-0005)
- Phase I Study of Repotrectinib and Osimertinib in NSCLC PatientsRecruitingPhase 1Instituto Oncológico Dr RosellNCT04772235Written as Repotrectinib
- A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)Active, not recruitingPhase 3Bristol-Myers SquibbNCT06140836Written as Repotrectinib
- Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT07223671Written as Repotrectinib
- Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)TerminatedPhase 2M.D. Anderson Cancer CenterNCT06408168Written as Repotrectinib
- A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic ImpairmentCompletedPhase 1Bristol-Myers SquibbNCT06352528Written as Repotrectinib
- A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT06493409Written as Repotrectinib
- A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid TumorsWithdrawnPhase 1Turning Point Therapeutics, Inc.NCT05828303Written as TPX-0005
- A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid TumorsTerminatedPhase 1/2Turning Point Therapeutics, Inc.NCT05071183Written as TPX-0005
- A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer PatientsWithdrawnPhase 1Turning Point Therapeutics, Inc.NCT05828277Written as repotrectinib (TPX-0005)
Codes
What other systems call repotrectinib · ClinicalTrials.gg INT001361
- MeSH (NLM) C000708510repotrectinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 08O3FQ4UNPREPOTRECTINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q123499554repotrectinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C133821RepotrectinibOne source FDA
- DrugBank DB16826One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000708510 | repotrectinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 08O3FQ4UNP | REPOTRECTINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q123499554 | repotrectinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C133821 | Repotrectinib | One source FDA |
| DrugBank | DB16826 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.